Form 8-K - Current report:
SEC Accession No. 0001628280-25-049865
Filing Date
2025-11-06
Accepted
2025-11-06 07:30:49
Documents
14
Period of Report
2025-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cbio-20251106.htm   iXBRL 8-K 27951
2 EX-99.1 pressrelease-q32025.htm EX-99.1 56092
6 image_0a.jpg GRAPHIC 56799
  Complete submission text file 0001628280-25-049865.txt   286103

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cbio-20251106.xsd EX-101.SCH 1800
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cbio-20251106_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cbio-20251106_pre.xml EX-101.PRE 12520
16 EXTRACTED XBRL INSTANCE DOCUMENT cbio-20251106_htm.xml XML 2716
Mailing Address 300 FIFTH AVENUE WALTHAM MA 02451
Business Address 300 FIFTH AVENUE WALTHAM MA 02451 617-430-5595
CRESCENT BIOPHARMA, INC. (Filer) CIK: 0001253689 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36177 | Film No.: 251456162
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)